The Michael J. Fox Foundation’s Parkinson’s Disease Therapeutics Conference 2026
Join us at The Michael J. Fox Foundation’s Parkinson’s Disease Therapeutics Conference (PDTC) in NYC from October 14-15, 2026.
Meet our neuroscience experts at PDTC to discover how P95 Julius Clinical supports efficient, high-quality research across complex neurological and psychiatric conditions. Our team partners with sponsors to navigate the unique challenges of neuroscience drug development, delivering tailored strategies that accelerate timelines while maintaining scientific rigor.
From clinical development through evidence generation, we help organizations build the insights needed to advance innovative therapies, better understand patient outcomes, and support informed decision-making throughout the product lifecycle.
Let’s Meet in New York!
Connect with our team at PDTC 2026 to discuss how we can support your next Parkinson’s disease clinical trial.
Our Partnership with The Michael J. Fox Foundation (MJFF)
P95 Julius Clinical is proud to support MJFF’s mission to accelerate breakthroughs for people living with Parkinson’s disease. As the clinical operations partner for the Foundation’s Path to Prevention (P2P) platform trial, we are collaborating with MJFF and global research partners to evaluate investigational therapies aimed at slowing or preventing Parkinson’s disease before symptoms emerge. This innovative study leverages years of Parkinson’s biomarker and clinical research to help advance a new era of earlier intervention and precision medicine in Parkinson’s disease.
Learn more about our work with MJFF and the Path to Prevention trial.
Advancing Neuroscience Research with Confidence
P95 Julius Clinical offers comprehensive support across the research continuum. With deep expertise in central nervous system diseases, we help bring innovative therapies to patients faster. From clinical trial design and execution to real-world evidence generation, we provide an integrated approach that helps sponsors answer critical research questions and optimize outcomes across the product lifecycle.
Explore our neuroscience expertise.
Explore our real-world evidence expertise.
Why P95 Julius Clinical?
Neuroscience research presents distinct challenges, from complex endpoints and patient variability to understanding treatment outcomes in real-world settings. P95 Julius Clinical combines scientific expertise, operational precision, and evidence-generation capabilities to address these challenges effectively.
With our strong global network and experienced in-house teams, we deliver customized solutions spanning clinical trials, observational research, and real-world evidence, ensuring high-quality data and actionable insights aligned with your development goals.
Related events
ESC Congress 2026
Join P95 Julius Clinical at the European Society of Cardiology Congress 2026 in Munich from August 28-31, 2026. Meet our cardiometabolic experts at the 2026 ESC Congress to discover how P95 Julius Clinical supports efficient, high-quality clinica...
MASH Drug Development Summit 2026
Join P95 Julius Clinical at MASH Drug Development Summit 2026 in Boston from September 15-17, 2026. Meet our cardiometabolic experts at the 2026 MASH Summit to discover how P95 Julius Clinical supports efficient, high-quality clinical trials acro...
ECNP Congress 2026
Join P95 Julius Clinical at the European College of Neuropsychopharmacology (ECNP) Congress in Munich, Germany from October 10-13, 2026. Meet our neuroscience experts at the 2026 ECNP Congress to discover how P95 Julius Clinical supports efficien...